Klaus M Uller

Title: Klaus M Uller: Innovator in Guanidine Derivatives

Introduction

Klaus M Uller is a notable inventor based in Münchenstein, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have important medical applications. With a total of 2 patents, Uller's work focuses on innovative solutions to enhance health outcomes.

Latest Patents

Uller's latest patents involve Guanidine derivatives, which are compounds designed to inhibit thrombin-induced platelet aggregation and clotting of fibrinogen in plasma. These compounds are characterized by the formula ##STR1##, where L, M, R, T, and X are specified in the detailed description. The preparation of these compounds involves amidination or, depending on whether L is NH or O, amide formation or esterification. This innovative approach has the potential to significantly impact treatments related to blood clotting disorders.

Career Highlights

Klaus M Uller is currently associated with Hoffmann-La Roche Inc., a leading global healthcare company. His work at this esteemed organization has allowed him to focus on groundbreaking research and development in the pharmaceutical sector. Uller's expertise and dedication to innovation have positioned him as a key figure in his field.

Collaborations

Uller has collaborated with notable colleagues, including Jean Ackermann and David Banner. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in research.

Conclusion

Klaus M Uller's contributions to the field of pharmaceuticals, particularly through his patents on Guanidine derivatives, highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments, showcasing the importance of innovation in healthcare.